Richard R Weiss Net Worth

The estimated Net Worth of Richard R Weiss is at least $1.14 Milion dollars as of 15 February 2012. Richard Weiss owns over 20,400 units of Simulations Plus stock worth over $1,142,182 and over the last 20 years Richard sold SLP stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Richard Weiss SLP stock SEC Form 4 insiders trading

Richard has made over 1 trades of the Simulations Plus stock since 2012, according to the Form 4 filled with the SEC. Most recently Richard exercised 20,400 units of SLP stock worth $25,500 on 15 February 2012.

The largest trade Richard's ever made was exercising 20,400 units of Simulations Plus stock on 15 February 2012 worth over $25,500. On average, Richard trades about 1,569 units every 0 days since 2004. As of 15 February 2012 Richard still owns at least 34,812 units of Simulations Plus stock.

You can see the complete history of Richard Weiss stock trades at the bottom of the page.

What's Richard Weiss's mailing address?

Richard's mailing address filed with the SEC is 1220 W AVENUE J, , LANCASTER, CA, 93534.

Insiders trading at Simulations Plus

Over the last 21 years, insiders at Simulations Plus have traded over $70,055,940 worth of Simulations Plus stock and bought 24,000 units worth $1,395,840 . The most active insiders traders include Walter Swoltosz Virginia E ..., Walter S Woltosz oraz Momoko A Beran. On average, Simulations Plus executives and independent directors trade stock every 37 days with the average trade being worth of $571,025. The most recent stock trade was executed by Jill Fiedler Kelly on 9 September 2024, trading 2,250 units of SLP stock currently worth $21,848.

What does Simulations Plus do?

simulations plus, inc. (nasdaq: slp) is the premier developer of modeling & simulation software and consulting services supporting drug discovery, development research and regulatory submissions. we partner with companies to provide a data-driven, ‘strategic modeling methodology’, starting in early discovery, continuing through preclinical/clinical development, and concluding with clinical trials/post approval. with our subsidiaries, cognigen corporation and dilisym services, we offer #1-ranked, easy-to-use software (gastroplus™, admet predictor™, kiwi™, dilisym®, nafldsym®, pkplus™, and more) to bridge data mining, compound library screening with qsar models, pbpk/tk modeling & simulation in animals and humans following administration around the body, and quantitative systems pharmacology approaches. simulations plus technology is licensed to and used by regulatory agencies worldwide. for over 20 years, simulations plus has partnered with our clients to reduce costs and accelerate res

Complete history of Richard Weiss stock trades at Simulations Plus

Simulations Plus executives and stock owners

Simulations Plus executives and other stock owners filed with the SEC include:

• Shawn M. O'Connor,
  Chief Exec. Officer
• Shawn O'Connor,
  Chief Executive Officer
• William Frederick,
  CFO & Sec.
• John DiBella,
  President, Lancaster Division
• John Anthony DiBella M.S.,
  Pres of Lancaster Division
• Thaddeus Grasela,
  Senior Advisory Capacity
• John Kneisel,
  Chief Financial Officer
• Jill Fiedler-Kelly M.S., MS,
  Pres of Cognigen Division
• Dr. Brett A. Howell Ph.D.,
  Pres of DILIsym Services, Inc
• Dr. Brett A. Howell,
  Pres of DILIsym Services, Inc
• John Paglia,
  Independent Director
• Daniel Weiner,
  Independent Director
• David Ralph,
  Independent Director
• Walter Woltosz,
  Chairman of the Board
• Walter S. Woltosz M.A.S., M.S.,
  Co-Founder & Chairman
• Lisa LaVange,
  Independent Director
• Renee Bouche,
  IR Contact Officer
• Jill Fiedler-Kelly,
  President - Cognigen division
• Dr. Scott Q. Siler,
  Chief Scientific Officer of DILIsym Services, Inc
• Lindsay Luke,
  Exec. Director of HR
• Arlene Padron,
  Corp. Director of Marketing
• Viera Lukacova Ph.D.,
  Chief Scientific Officer
• Argenio David Z D,
  Director
• Brett Howell,
  Business Unit President
• Steven Chang,
  President, Immunetrics
• William W Frederick,
  CFO
• Walter Swoltosz Virginia E ...,
  
• Walter S Woltosz,
  Director
• Richard R Weiss,
  Director
• Momoko A Beran,
  Chief Financial Officer
• Harold Wayne Rosenberger,
  Director
• Jeffrey A Dahlen,
  VP, Research & Development
• Virginia E Woltosz,
  Secretary/Treasurer
• Ronald F Creeley,
  VP Marketing & Sales
• Daniel Szot,
  Chief Revenue Officer
• Sharlene Evans,
  Director